Incretin mimetics
The GLP-1 receptor agonist lixisenatide may slow the progression of Parkinson’s: in a phase II study, the disease did not progress over a year. However, side effects such as nausea and vomiting may limit its use.
cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk cuk
The GLP-1 receptor agonist lixisenatide may slow the progression of Parkinson’s: in a phase II study, the disease did not progress over a year. However, side effects such as nausea and vomiting may limit its use.